Real World Evaluation of Sotorasib among Chinese Non-Small Cell Lung Cancer Patients (20240175)

Study identification

• EU PAS number:
  EUPAS1000000636
• Study ID:
  1000000636
• Official title and acronym:
  Real World Evaluation of Sotorasib among Chinese Non-Small Cell Lung Cancer Patients (20240175)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  No information provided.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Amgen

United States

Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine, Boao Super Hospital, Boao Evergrande International Hospital, Boao Vanguard Hospital

Study timelines

Date when funding contract was signed

Planned:15/07/2025

Study start date

Planned:11/08/2025

Actual:11/08/2025

Data analysis start date

Planned:02/02/2026

Actual:02/02/2026

Date of final study report

Planned:31/07/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen Inc

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

20240175